Hepatology | Home | MIMS Malaysia

Hepatology

Portal hypertension persistent in over half of HCV patients even after SVR

an hour ago

Clinically significant portal hypertension may persist for weeks in about half of patients with hepatitis C virus (HCV)-related cirrhosis, even after sustained virological response (SVR) has been achieved, a new study has found. This may indicate that risk of decompensation remains.

Lanifibranor efficacy in NASH evident in diabetics and non-diabetics

Roshini Claire Anthony, 12 hours ago

The efficacy of lanifibranor in reducing histological markers of non-alcoholic steatohepatitis (NASH) is comparable in patients with and without type 2 diabetes (T2D), according to the phase IIb NATIVE study presented as a poster at AASLD 2020.

Seladelpar improves histologic, biochemical responses in NASH patients

Audrey Abella, 20 hours ago

Use of the potent and selective PPARδ* agonist seladelpar led to improvements in histologic responses and liver chemistry in patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH), a phase II study has shown.

Managing hepatitis in primary care

Yesterday

Dr Rajneesh Kumar, a senior consultant at the Department of Gastroenterology and Hepatology, Singapore General Hospital, highlights the high prevalence of hepatitis, and speaks to Roshini Claire Anthony about the transmission, prevention, and treatment of the disease.

Inflammatory markers tied to better HCC outcomes after nivolumab treatment

Yesterday

Following treatment with nivolumab, a programmed death (PD)-1 inhibitor, the expression of inflammatory markers seems to correlate with better survival and treatment response in hepatocellular carcinoma (HCC) patients, a recent study has shown. This suggests that antitumour inflammatory mechanisms play a role in the action of nivolumab.

Durable treatment response seen with dapagliflozin-saxagliptin add-on in T2D patients on metformin

Audrey Abella, 2 days ago

Reductions in liver fat and adipose tissue volumes were sustained in patients with type 2 diabetes (T2D) with the addition of the SGLT-2* inhibitor dapagliflozin (DAPA) and the DPP-4** inhibitor saxagliptin (SAXA) to metformin (MET), compared with a regimen comprising glimepiride (GLIM)+MET, according to the extension period results of a phase IIIb trial.

Low liver fat bad for the heart?

Pearl Toh, 4 days ago

Distribution of body fat can affect a person’s risk of coronary heart disease (CHD), suggests a study presented at the AASLD 2020 Liver Meeting, which shows that people with high abdominal fat but low liver fat have an increased risk of CHD events than those with other fat distribution.

Reducing risks and improving long-term outcomes in patients with CHB

Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 10 Sep 2019

Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.

Relationship between tumour response to systemic therapy and overall survival in unresectable hepatocellular carcinoma

Dr Raghav Sundar, 09 Sep 2019

Overall survival (OS) is currently the primary criteria in assessing the efficacy of a cancer treatment. Dr Raghav Sundar, a consultant medical oncologist at the National University Hospital, Singapore, details the crucial role played by tumour response in evaluating treatment efficacy, with a focus on the multiple kinase inhibitor lenvatinib in the treatment of hepatocellular carcinoma (HCC).

Lanifibranor efficacy in NASH evident in diabetics and non-diabetics

Roshini Claire Anthony, 27 Nov 2020

Seladelpar improves histologic, biochemical responses in NASH patients

Audrey Abella, 27 Nov 2020

Durable treatment response seen with dapagliflozin-saxagliptin add-on in T2D patients on metformin

Audrey Abella, 25 Nov 2020

TAF during pregnancy curbs HBV transmission from mother to child

Pearl Toh, 21 Nov 2020

Antiviral treatment with tenofovir alafenamide fumarate (TAF) during pregnancy in highly viraemic mothers effectively prevents mother-to-child transmission (MTCT) of hepatitis B virus (HBV) with no safety concerns, according to two studies presented during the AASLD 2020 Liver Meeting.

Neural network model predicts death among patients on liver transplant waitlist

Stephen Padilla, 19 Nov 2020

A type of machine learning algorithm using neural networks (NN) appears more accurate than the older model for end-stage liver disease (MELD) scoring in predicting mortality among patients on the liver transplant (LT) waitlist, according to a study.

Novel fatty acid synthase inhibitor for NASH makes good in early trial

Jairia Dela Cruz, 18 Nov 2020

The small molecule fatty acid synthase inhibitor TVB-2640 boasts a win in addressing the three key drivers of nonalcoholic steatohepatitis (NASH)—namely liver fat, fibrosis, and inflammation—in the phase II FASCINATE-1 trial presented during The Liver Meeting Digital Experience of the American Association for the Study of Liver Diseases (AASLD).

Low liver fat may be bad for the heart

Stephen Padilla, 18 Nov 2020

The distribution of body fat contributes to the risk of coronary heart disease (CHD), with the risk of cardiovascular events further increasing among individuals with low liver fat (LF) and high visceral adipose tissue (VAT) or abdominal fat, results of a recent study have shown.

Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!